Lantern Pharma (LTRN) Set to Announce Quarterly Earnings on Wednesday

Lantern Pharma (NASDAQ:LTRN – Get Free Report) is expected to be posting its Q3 2026 resultson Wednesday, November 11th. Analysts expect Lantern Pharma to post earnings of ($0.35) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:00 AM ET.

Lantern Pharma (NASDAQ:LTRN – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.19).

Lantern Pharma Trading Up 5.5%

NASDAQ LTRN opened at $0.60 on Tuesday. Lantern Pharma has a 12 month low of $0.50 and a 12 month high of $4.34. The stock has a market cap of $8.95 million, a P/E ratio of -0.37 and a beta of 2.48. The stock’s fifty day moving average price is $1.11 and its 200-day moving average price is $2.39.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on LTRN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lantern Pharma in a research report on Tuesday, October 27th. Wall Street Zen downgraded shares of Lantern Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has an average rating of “Sell”.

View Our Latest Stock Report on LTRN

Lantern Pharma Company Profile

(Get Free Report)

Lantern Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing precision cancer therapies. The company combines artificial intelligence, machine learning and genomic analysis to identify drug candidates, patient populations and biomarkers that may support more targeted oncology treatments.

Lantern Pharma’s technology platform, RADR, is designed to analyze large volumes of biological, genomic and clinical data to help accelerate drug discovery and development. The platform is used to evaluate existing and novel therapeutic compounds, identify potential mechanisms of action and support the development of biomarker-driven clinical programs.

The company’s oncology pipeline has included investigational therapies for solid tumors and hematologic cancers, including programs such as LP-184 and LP-284.

Read More

Earnings History for Lantern Pharma (NASDAQ:LTRN)

Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.